TNFRSF10B and neoplasm: To investigate clinical human DR5 agonist using in vivo heterogeneous mixed tumor graft condition, we engineered chimeric DR5 constructs, with extracellular domain (ECD) of human DR5 fused with mouse DR5 transmembrane (TM) and intracellular domain (ICD; Fig 5A).